ZBH Stock Recent News
ZBH LATEST HEADLINES
ZBH's Hips business is expected to have witnessed growth banking on its suite of navigation solutions in direct anterior stems and surgical impactors.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. (NYSE: ZBH). Under the terms of the proposed transaction, shareholders of Paragon will receive $13.00 in cash as well as a non-tradeable contingent value right, entitling the holder to receive up to $1.00 per share in cash if certain revenue mileston.
Zimmer Biomet said on Tuesday it would acquire medical device company Paragon 28 for about $1.1 billion.
Zimmer Biomet is witnessing strong market share gains within reconstructive Knees and Hips in key geographies despite macroeconomic challenges.
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.
Zimmer Biomet Holdings (ZBH) is expanding its product portfolio and improving cash flow, positioning it for long-term profitability and financial health. ZBH is undervalued compared to peers, with significant growth potential driven by innovation, acquisitions, and operational efficiency improvements. The company's focus on high-growth markets and improving profitability metrics indicate a strong future outlook, despite past underperformance.
Zimmer Biomet's third-quarter results are likely to reflect the strength in its three business segments, namely Hips, Knees and S.ET.
WARSAW, Ind. , Oct. 9, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, October 30, 2024 at 8:30 a.m.
Dublin, Oct. 07, 2024 (GLOBE NEWSWIRE) -- The "Large Joint Devices Market Size, Share, and Trends Analysis Global 2024-2030 MedSuite Includes: Knee Replacement Market, Hip Replacement Market, and 1 more" report has been added to ResearchAndMarkets.com's offering.
Zimmer Biomet, a leader in musculoskeletal health, excels in knee and hip replacements, and surgical robots, making it a sticky choice for many orthopedic surgeons. Competitive advantages include strong surgeon loyalty, technological innovation with the ROSA® Robot, and a global consignment-based distribution model ensuring product availability. Challenges include regulatory hurdles, reliance on elective surgeries, supply chain risks, and fierce competition from companies like Stryker.